Results 81 to 90 of about 96,094 (164)

Progression-Free Survival with PARP Inhibitors According to Clinical Risk in Patients with Ovarian Cancer: An Indirect Comparison Using Reconstructed Data. [PDF]

Oncol Res
Gasperoni L, Del Bono L, Farolfi A, Messori A, Damuzzo V.   +4 more
europepmc   +1 more source

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source

Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α. [PDF]

Redox Biol
Yang T, Bu W, Xue X, Wu X, Zhou Y, Chen Y, Li Y, Zhang J, Li P, Shen F, Shi Y, Shao C.   +11 more
europepmc   +1 more source

Post-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar. [PDF]

Front Immunol
Bentebbal S, Zaqout A, Meqbel B, Bensmail I, Aldushain A, de la Fuente A, Thomas R, Naik A, Shaath H, Al-Akl NS, Adam A, Moussa HYA, Shin KC, Taha RZ, Abukhattab M, Al-Maslamani MA, Alajez NM, Arredouani A, Park Y, Abdulla SA, El-Agnaf OMA, Abdesselem HB, Omrani AS, Decock J.   +23 more
europepmc   +1 more source

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy. [PDF]

Hum Mutat
Shen Q, Wang Y, Cai L, Qian J.
europepmc   +1 more source

PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges. [PDF]

Cells
Matsuoka T, Akamatsu S, Ong CJ, Gleave ME, Wang Y.   +4 more
europepmc   +1 more source

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. [PDF]

Clin Cancer Res
Huffman BM, Diossy M, Yurgelun MB, Horick N, Li YY, Crowdis J, Nguyen H, Parmar K, Kochupurakkal BS, Vonk L, Lam H, Ramsey K, Andrews E, Loeb SC, Culnane L, Biller LH, Bullock AJ, Enzinger A, Giannakis M, Jackson NA, Ng K, Nowak JA, Patel AK, Perez KJ, Rattani A, Rubinson DA, Schlechter BL, Singh H, Cai M, Raghavan S, Clark JW, Peters ML, Weipert CM, Wolpin BM, D'Andrea AD, Shapiro GI, Aguirre AJ, Szallasi Z, Cleary JM.   +38 more
europepmc   +1 more source

Differential sensitivity of MCPH1- and BRCA2-deficient cancer cells to PARP-1 inhibition. [PDF]

PLoS One
Chapman IG, Wu X, Veuger S, Jowsey PA.
europepmc   +1 more source